



NDA 021882/S-033

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENT**

Novartis Pharmaceuticals Corporation
Attention: Smita Abbi, PhD
Senior Global Program Manager, Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Abbi:

Please refer to your supplemental new drug application (sNDA) dated and received September 23, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for EXJADE (deferasirox) tablets.

This Prior Approval supplemental new drug application provides for an update to the Exjade US Prescribing Information based the results from clinical study report for clinical study ICL670E2419 (THETIS), which support PMRs 1994-1, 1994-2 and 1994-6, and converting the non-transfusion dependent thalassemia (NTDT) indication from accelerated approval under Subpart H to traditional approval.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

SUBPART H FULFILLED

We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitments made under 21 CFR 314.510.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated September 23, 2019, containing the final report for the following postmarketing requirements listed in the January 23, 2013, approval letter.

PMR 1994-1 Conduct a trial to assess the long-term efficacy of Exjade (deferasirox) in patients with NTDT and high LIC. The trial should assess response rates in the subset of patients with baseline LIC values >15 mg Fe/g dw (proportion of patients achieving an LIC <5 mg Fe/g dw and time to achieving an LIC <5 mg Fe/g dw). Follow-up of all subjects for up to 5 years is necessary.

PMR 1994-2 Assess the long-term efficacy (and safety) of Exjade (deferasirox) treatment to a target LIC of 3 mg Fe/g dw followed by one or more treatment holidays until the LIC is ≥ 5 mg Fe/g dw in patients with NTDT. Follow-up of all subjects for up to 5 years is necessary.

PMR 1994-6 Assess the long-term safety of Exjade (deferasirox) in patients with NTDT by conducting a trial of Exjade (deferasirox) for the treatment of iron overload (LIC ≥ 5 mg Fe/g dw) in non-transfusion dependent thalassemia (NTDT) in patients aged 10 years and greater with up to 5 years total follow-up.

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements and commitments that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Martin White, M.S., Regulatory Project Manager, at (240) 402-6018.

Sincerely,

{See appended electronic signature page}

Albert Deisseroth, MD, PhD
Supervisory Associate Director
Division of Nonmalignant Hematology
Office of Cardiology, Hematology,
Endocrinology, & Nephrology
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ALBERT B DEISSEROTH
07/23/2020 05:19:27 PM